Pfizer Inc
Research Pfizer Inc (PFE) on Bullrun: valuation model: 23.0% overvalued, market cap USD 162.82B, P/E 37.8, dividend yield 6.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPFE
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal23.0% overvalued
- Market capUSD 162.82B
- P/E37.8
- Dividend yield6.1%
- Financial periodQ2 2026
- RevenueUSD 15.03B
- Net income-USD 248.00M
- Free cash flowUSD 302.00M
- Gross margin72.8%
Valuation Snapshot
Bullrun's latest valuation model marks Pfizer Inc as 23.0% overvalued; latest market cap is USD 162.82B; P/E is 37.8; dividend yield is 6.1%.
Peer valuation comparison
Latest P/E is 37.83x versus a Healthcare sector median of 24.46x (54.7% above).
Latest dividend yield is 6.14% versus a Healthcare sector median of 2.11% (191.0% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 62.58B | USD 7.77B | USD 9.08B | 74.3% | 1.36 | USD 1.14B | USD 64.80B | USD 86.48B |
| FY2024 | USD 63.63B | USD 8.03B | USD 9.84B | 71.9% | 1.41 | USD 1.04B | USD 64.35B | USD 88.20B |
| FY2023 | USD 50.91B | USD 2.12B | USD 4.79B | 51.0% | 0.37 | USD 2.85B | USD 71.89B | USD 89.01B |
| FY2022 | USD 91.79B | USD 31.37B | USD 26.03B | 62.6% | 5.47 | USD 416.00M | USD 35.83B | USD 95.66B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 162.82B | 37.8 | 6.0% | 1.72 |
| 2025 | 2025-12-31 | USD 141.58B | 18.3 | 6.9% | 1.72 |
| 2024 | 2024-12-31 | USD 150.35B | 18.8 | 6.3% | 1.68 |
| 2023 | 2023-12-29 | USD 162.56B | 15.8 | 5.7% | 1.64 |
| 2022 | 2022-12-30 | USD 287.63B | 9.9 | 3.1% | 1.6 |
| 2021 | 2021-12-31 | USD 331.86B | 15.1 | 2.6% | 1.56 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.72 USD, yield 6.1%.
| Year | Dividends/share |
|---|---|
| FY2025 | 1.72 USD |
| FY2024 | 1.69 USD |
| FY2023 | 1.65 USD |
| FY2022 | 1.61 USD |
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Pfizer Inc overvalued or undervalued?
Bullrun's valuation model currently marks Pfizer Inc as 23.0% overvalued.
What is Pfizer Inc's market cap?
Pfizer Inc's market capitalization is USD 162.82B.
What is Pfizer Inc's P/E ratio?
Pfizer Inc's price-to-earnings (P/E) ratio is 37.8.
Does Pfizer Inc pay a dividend?
Pfizer Inc has a dividend yield of 6.1%.
What does Pfizer Inc do?
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19.